argenx signs agreement to buy Forte Biosciences for $2.2bn
argenx agreed to acquire Forte Biosciences for about $2.2bn total equity value. The deal, approved by both boards, is expected to close in Q3 2026 subject to conditions. argenx will tender for all Forte shares at $77 each, an ~86% premium. Forte’s lead asset FB102 (anti-CD122) is in Phase Ib and plans Phase II data in 2H 2026.
How this was made
The 30-second read
Why it matters
The definitive agreement, offer price ($77) and premium, and cash-funded tender offer provide actionable deal-spread and event-risk inputs. The next major fundamental inflection is expected Phase II data for FB102 in H2 2026, which could validate or challenge the acquisition thesis.
Market read
Definitive M&A terms with a large premium and a cash-funded tender offer make this a high-signal, time-sensitive event for deal-risk positioning.
What to watch
Phase II data for FB102 is expected in the second half of 2026, so the market may reprice the strategic value of the acquisition as clinical readouts approach.
Background
argenx is expanding its immunology antibody portfolio via acquisition of Forte Biosciences’ lead asset FB102, following Phase Ib evaluation in vitiligo and celiac disease.
Ticker impact
argenx agreed to buy Forte Biosciences for about $2.2bn, launching a cash tender offer at $77 per share to add FB102 to its immunology portfolio.
Likely supportive for ARGX on deal premium and cash-funded structure, with volatility around tender acceptance and regulatory timing.
The article discloses definitive acquisition terms, offer price premium, cash funding without financing conditions, and expected Q3 2026 close, which are direct drivers of deal-spread and headline sentiment.
Market effects
Reinforces consolidation in immunology/antibody therapeutics and may raise competitive expectations for next-phase CD122 and broader immunology pipelines.
Limited direct regional impact, but includes mention of NMPA approval for efgartigimod SC in China.
Cross-border biotech M&A signal, with potential read-through to valuation and deal appetite in antibody platforms.
Counterpoint
Even with a cash-funded offer, deal completion risk (tender thresholds and regulatory waiting periods) can keep ARGX and deal targets volatile until approvals clear.
Key entities
- acquirerargenx
Entered a definitive agreement to acquire Forte Biosciences for about $2.2bn and will begin a cash tender offer at $77 per share.
- targetForte Biosciences
Will be acquired by argenx; its lead asset is FB102, an anti-CD122 antibody.
- assetFB102
First-in-class anti-CD122 antibody; evaluated in Phase Ib for vitiligo and celiac disease, with Phase II data expected in H2 2026.
